Effects of Oral Care With Glutamine on Oral Health, Oral Flora and Incidence of Pneumonia After Neurosurgery With Microbiome Analysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-01

Study Completion Date

2024-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, double-blind, single-center and controlled study comparing the efficacy and safety of intravenous administration of tranexamic acid to reduce blood loss in simultaneous bilateral total knee arthroplasty.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Acute Radiation Enteritis With Glutamine

NCT00828399

Acute Radiation Enteritis

COMPLETED PHASE4

Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity

NCT03180775

Atherosclerosis Diet Modification Serum; Disease

UNKNOWN NA

Safety and Efficacy of Adding Intravenous N-acetyl Cysteine in Colon Surgeries

NCT03589495

Systemic Inflammatory Response Syndrome

COMPLETED PHASE4

Effect of Gutamine Administration in the Innate Immune System Response in ICU Patients.

NCT01250080

Moderate to Severe Trauma, as Defined by an Injury Severity Score (ISS) > 12 Points Were Included in the Study.

COMPLETED NA

Glutamate Supplementation in Young Men

NCT03425578

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomized, double-blind, single-center and controlled study comparing the efficacy and safety of intravenous administration of tranexamic acid to reduce blood loss in simultaneous bilateral total knee arthroplasty. Subjects will be monitored for occurrence of any complications, particularly deep venous thrombosis and thromboembolism during the hospital stay and for 1 months postoperatively

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Mucositis Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

Receiving TXA, Study group

Tranexamic acid, Study group tranexamic acid 1g,

intravenous injection, pre-operationally

Group Type EXPERIMENTAL

Glutamine

Intervention Type DRUG

1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision

Placebo Comparator

Normal saline, Control group

Not receiving tranexamic acid, Control group Normal

saline 100mL, intravenous injection, pre-operationally

Group Type PLACEBO_COMPARATOR

Normal saline

Intervention Type DRUG

100 mL of normal saline intravenously approximately 15 minutes before incision

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glutamine

1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision

Intervention Type DRUG

Normal saline

100 mL of normal saline intravenously approximately 15 minutes before incision

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients who plan to undergo simultaneous primary total knee arthroplasty on bilateral knee joint with a diagnosis of osteoarthritis or aseptic bone necrosis, but not of rheumatoid arthritis;
* All patients who have normal preoperative platelet count, normal prothrombin time, normal partial thromboplastin time, and normal international normalized ratio;
* The use of only balanced electrolyte solutions and/or albumin for plasma volume restitution.

Exclusion Criteria

* Allergy to tranexamic acid;
* Receiving warfarin or heparin; had a history of hemophilia, deep venous thrombosis, pulmonary embolism, or renal impairment; or were pregnant;
* Patients with any cardiovascular problems (such as myocardiac infarction history, atrial fibrillation, angina);
* Patients with thromboembolic disorders, or those exhibiting a deteriorating general condition;
* Preoperative anemia (a hemoglobin value of \<11 g/dL in females and \<12 g/dL in males), refusal of blood products;
* Preoperative use of anticoagulant therapy within five days before surgery, fibrinolytic disorders requiring intraoperative antifibrinolytic treatment, coagulopathy (as identified by a preoperative platelet count of \<150,000/mm3, an international normalized ratio of \>1.4, or a prolonged partial thromboplastin time \[\>1.4 times normal\]).

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No